Extended Nirmatrelvir/Ritonavir Beneficial for Some With Long COVID
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 8, 2025 -- Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist, according to a case series published online Jan. 6 in Communications Medicine.
Alison K. Cohen, Ph.D., M.P.H., from the University of California San Francisco, and colleagues documented a case series of 13 individuals with long COVID who initiated extended courses (more than five days; range, 7.5 to 30 days) of oral nirmatrelvir/ritonavir outside of and within (11 and two individuals, respectively) the context of an acute severe acute respiratory syndrome coronavirus 2 infection.
The researchers found that some of those taking an extended course of nirmatrelvir/ritonavir outside the context of an acute infection experienced a meaningful reduction in symptoms, but not all benefits persisted. No effect on symptoms was experienced by the other individuals in this group. Due to intense stomach pain, one participant stopped taking the medication early. Both participants who took an extended course of nirmatrelvir/ritonavir within the context of an acute reinfection reported eventually returning to their pre-reinfection baseline.
"These cases provide strong rationale for the ongoing study of antivirals for long COVID to determine if, when, and how they should be used in this patient population," the authors write.
One author disclosed ties to Gilead Sciences and AstraZeneca.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Further Support and Information on COVID-19
Read this next
Prevalence of Most Cancer Risk Factors Unchanged Before, After Pandemic
THURSDAY, April 24, 2025 -- Smoking rates continued to decline during the COVID-19 pandemic, but other major risk factors for cancer remained stable, according to a study...
Eviction Moratoria Reduced Child Maltreatment Rates During Pandemic
WEDNESDAY, April 16, 2025 -- Bans on evictions put in place during the COVID-19 pandemic seemed to reduce child maltreatment, according to a study published online April 8 in...
Hurricanes, Pandemic Led to Drop in CRC Incidence in Puerto Rico
MONDAY, April 14, 2025 -- Recent major events, including hurricanes Irma and Maria and the COVID-19 pandemic, were associated with a decreased incidence of colorectal cancer (CRC)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.